Predicting the best immune system stimulating regions of HIV Vif protein in Iranian patients

Document Type : Original Research

Authors

Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract
Background:

HIV has at least six regulatory genes among which the Vif protein can control HIV replication. This study, as the first report, investigated the important mutations in VIF protein in sequences from Iranian patients and using immunoinformatics, conserved regions of this protein and B-Cell, T-Cell and CTL epitopes to stimulate the immune system, were determined.

Methods:

VIF sequences were obtained from NCBI GenBank, and tertiary structures, B-Cell, T-Cell and CTL epitopes were predicted by bioinformatics tools; besides, their antigenic and allergenic properties were studied.

Results:

The most prevalent mutations in Vif protein were related to S 49 P (90%), S 140 N and N 186 S (80%). Two substitutions at positions 41 and 42 were introduced which have effect on Vif binding to host factor. In addition, three regions were identified as the best epitope sequences with high potential to induce immune system and the lowest allergic properties, among which 5-32 region was suggested as the best vaccine candidate regions.

Conclusion:

This study as the first study from Iran using immunoinformatics tools to introduced a region with the high potential to induce humoral and cellular immune systems and lowest allergenic properties which can be used for further studies on HIV vaccines.

Keywords

Subjects


1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annual review of immunology. 1999;17(1):657-700.
2. Dehghani B, Hasanshahi Z, Hashempour T. HIV Capsid and Protease, New Targets of Melittin. International Journal of Peptide Research and Therapeutics. 2020.
3. Hasanshahi Z, Dehghani B, Hashempour T. Bioinformatics Study of HIV-1 Integrase Gene Sequences in Iranian Patients. Pathobiology Research. 2020;23(2):57-65.
4. Nielsen MH, Pedersen FS, Kjems J. Molecular strategies to inhibit HIV-1 replication. Retrovirology. 2005;2:10-.
5. Reddy K, Ooms M, Letko M, Garrett N, Simon V, Ndung'u T. Functional characterization of Vif proteins from HIV-1 infected patients with different APOBEC3G haplotypes. AIDS. 2016;30(11):1723-9.
6. da Costa KS, Leal E, dos Santos AM, Lima e Lima AH, Alves CN, Lameira J. Structural analysis of viral infectivity factor of HIV type 1 and its interaction with A3G, EloC and EloB. PLoS One. 2014;9(2):e89116-e.
7. Hashempour T, Dehghani B, Mousavi Z, Yahaghi M, Hasanshahi Z, Moayedi J, et al. Evaluating drug resistant mutations to HCV NS3 protease inhibitors in iranian Naïve patients. International Journal of Peptide Research and Therapeutics. 2019:1-12.
8. Tayebeh H, Behzad D, Zahra M, Tahereh A, Zahra H, Javad M, et al. Association of mutations in the NS5A-PKRBD region and IFNL4 genotypes genotypes with hepatitis C interferon responsiveness and its functional and structural analysis. Current Proteomics. 2020;17:1-.
9. Dehghani B, Hasanshahi Z, Hashempour T, Motamedifar M. The possible regions to design Human Papilloma Viruses vaccine in Iranian L1 protein. Biologia. 2019:1-11.
10. Iwamoto N, Takahashi N, Seki S, Nomura T, Yamamoto H, Inoue M, et al. Control of Simian Immunodeficiency Virus Replication by Vaccine-Induced Gag- and Vif-Specific CD8<sup>+</sup> T Cells. Journal of Virology. 2014;88(1):425-33.
11. Geourjon C, Deléage G. SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. Computer applications in the biosciences : CABIOS. 1995;11(6):681-4.
12. Dehghani B, Hashempour T, Hasanshahi Z. Interaction of human herpesvirus 8 viral interleukin-6 with human interleukin-6 receptor using in silico approach: the potential role in HHV-8 pathogenesis. Current Proteomics. 2020;17(2):107-16.
13. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nature Protocols. 2010;5(4):725-38.
14. Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, et al. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res. 2019;47(D1):D339-D43.
15. Saha S, Raghava GPS. Prediction of continuous B‐cell epitopes in an antigen using recurrent neural network. Proteins: Structure, Function, and Bioinformatics. 2006;65(1):40-8.
16. Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 2017;45(W1):W24-w9.
17. Saha S, Raghava GPS, editors. BcePred: prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. International Conference on Artificial Immune Systems; 2004: Springer.
18. Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, et al. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 2018;154(3):394-406.
19. Paul S, Sidney J, Sette A, Peters B. TepiTool: A Pipeline for Computational Prediction of T Cell Epitope Candidates. Current protocols in immunology. 2016;114:18.9.1-.9.24.
20. Guan P, Doytchinova IA, Zygouri C, Flower DR. MHCPred: A server for quantitative prediction of peptide-MHC binding. Nucleic Acids Res. 2003;31(13):3621-4.
21. Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016;32(4):511-7.
22. Bhasin M, Raghava GP. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine. 2004;22(23-24):3195-204.
23. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC bioinformatics. 2007;8(1):4.
24. Dimitrov I, Naneva L, Doytchinova I, Bangov I. AllergenFP: allergenicity prediction by descriptor fingerprints. Bioinformatics. 2014;30(6):846-51.
25. Saha S, Raghava G. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res. 2006;34(suppl_2):W202-W9.
26. Du J, Wu X, Long F, Wen J, Hao W, Chen R, et al. Improvement in efficacy of DNA vaccine encoding HIV-1 Vif by LIGHT gene adjuvant. Viral immunology. 2013;26(1):68-74.
27. WIELAND U, KRATSCHMANN H, KEHM R, KÜHN JE, NÄHER H, KRAMER MD, et al. Antigenic domains of the HIV-1 vif protein as recognized by human sera and murine monoclonal antibodies. AIDS research and human retroviruses. 1991;7(11):861-7.
28. Iwamoto N, Takahashi N, Seki S, Nomura T, Yamamoto H, Inoue M, et al. Control of simian immunodeficiency virus replication by vaccine-induced Gag-and Vif-specific CD8+ T cells. Journal of virology. 2014;88(1):425-33.
29. Martins MA, Wilson NA, Piaskowski SM, Weisgrau KL, Furlott JR, Bonaldo MC, et al. Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239. Journal of virology. 2014;88(13):7493-516.
30. Pery E, Sheehy A, Nebane NM, Brazier AJ, Misra V, Rajendran KS, et al. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein. J Biol Chem. 2015;290(16):10504-17.